The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
Takeshi MatsumotoHideo WadaKatsuya ShirakiKei SuzukiYoshiki YamashitaIsao TawaraHideto ShimpoMotomu ShimaokaPublished in: Journal of clinical medicine (2023)
CWA-TT can be used to evaluate the thrombin bursts that cause hypercoagulability in patients treated with emicizumab. Although routine APTT evaluations demonstrated low coagulation ability in patients treated with FVIII concentrate, CWA-TT showed hypercoagulability in these patients, suggesting that the evaluation of coagulation ability may be useful when using multiple assays.